Samsung Biologics, U.S. Enzolytics Corona Treatment CDMO Contract
Samsung Biologics, U.S. Enzolytics Corona Treatment CDMO Contract
  • 이지선 기자
  • 승인 2021.10.11 20:26
  • 최종수정 2021.10.08 06:57
  • 댓글 0
이 기사를 공유합니다

 

&lt;사진=삼성바이오로직스&gt;<br>
&lt;사진=삼성바이오로직스&gt;<br>

Samsung BioLogics made an announcement on the 7th that it has signed a contract with US Engineers for consignment development and production (CDMO).

Under the deal, Samsung BioLogics will provide CDMO services for COVID-19 single antibody therapy under development by Enzolitics and a single antibody treatment for human immunodeficiency virus (HIV).

It provides one-stop support for cell line development, clinical material production, and clinical trial planning application (IND) support process.

Contracts will also be discussed for other antibody treatments under development by Enzoletics. Based on the artificial intelligence (AI) platform, Enzolitics is developing antibody treatments to respond to mutated viruses by targeting certain parts that remain unchanged in the virus.

Samsung BioLogics plans to support the development of cell lines of Enzoletics through the CDO (Pharmaceutical Consignment Development) R&D Center in San Francisco, USA.

Reporter Lee Ji-sun stockmk2020@gmail.com


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.